Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid-Dependent Crohnʼs Disease
Authors:
- Gerassimos J. MantzarisGMGerassimos J. Mantzaris
- Angeliki ChristidouACAngeliki Christidou
- Michael SfakianakisMSMichael Sfakianakis
- Anastassios RoussosARAnastassios Roussos
- Stavroula KoilakouSKStavroula Koilakou
- Kalliopi PetrakiKPKalliopi Petraki
- Paraskevi PolyzouPPParaskevi Polyzou
- 1 March 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 15 (3) , 375-382
Abstract
The effects of azathioprine (AZA) and budesonide (BUD) on mucosal healing and histologic remission of Crohn's disease (CD) are insufficiently studied. In this prospective study we evaluated the comparative effects of AZA and BUD on endoscopic and histologic activity in patients with steroid-dependent Crohn's ileocolitis or proximal colitis who had achieved clinical remission on conventional steroids. Patients were randomized to AZA (2.0-2.5 mg/kg a day) or BUD (6-9 mg a day) for 1 year. The study protocol included clinical examination, laboratory tests, calculation of the Crohn's Disease Activity Index (CDAI), completion of the Inflammatory Bowel Disease Questionnaire (IBDQ), at baseline and then every 2 months for 1 year. Ileocolonoscopy with regional biopsies was performed at baseline and then at the end of the study to assess mucosal healing and the histologic activity of CD. Thirty-eight patients were randomized to AZA and 39 to BUD. At the end of the study 32 and 25 patients in the AZA and BUD groups, respectively, were in clinical remission (P = 0.07). The Crohn's Disease Endoscopic Index of Severity (CDEIS) score fell significantly only in the AZA group (P < 0.0001). Complete or near complete healing was achieved in 83% of AZA-treated patients compared with only 24% of BUD-treated patients (P < 0.0001). Histologic activity as assessed by an average histology score (AHS) fell significantly only in the AZA group (P < 0.001 versus baseline) and was significantly lower than in the BUD group at the end of the study (P < 0.001). Eight patients in the AZA group were withdrawn for adverse events (n = 6) or relapse of disease compared with 14 patients in the BUD group who were withdrawn for relapse of disease. In patients with steroid-dependent inflammatory Crohn's ileocolitis or proximal colitis who achieve clinical remission with conventional steroids, a 1-year treatment with AZA was superior to BUD in achieving and maintaining mucosal healing and histologic remission.Keywords
This publication has 35 references indexed in Scilit:
- Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remissionAlimentary Pharmacology & Therapeutics, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohortAlimentary Pharmacology & Therapeutics, 2006
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Maintenance of Crohn’s disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsulesAlimentary Pharmacology & Therapeutics, 2001
- Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's diseaseGut, 2001
- Quality of Life Study in a Regional Group of Patients with Crohn Disease: A Structured Interview StudyScandinavian Journal of Gastroenterology, 2000
- Impact of Inflammatory Bowel Disease on Health-Related Quality of LifeDigestive Diseases, 1999
- Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.Gut, 1996